What are the mediators linking cardiometabolic risk factors and severe COVID-19?

FHS
August 2, 2023
12:11 pm

Researchers performed a genome-wide association study to explore whether biomarker levels are causally related to COVID-19 hospitalization.

Boehringer, Lilly secure EC approval for Jardiance to treat CKD

The trial assessed the effect of empagliflozin on kidney disease progression and cardiovascular mortality risk in 6,609 participants. Credit: Marko Aliaksandr / Shutterstock.com. Boehringer Ingelheim

July 26, 2023

Antidepressant prescriptions may reduce the risk of testing positive for COVID-19

New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has found that community mental health patients who were

June 21, 2023

We Don’t Always Know What’s ‘Best’ for Our Patients

Listen and subscribe/follow on Apple and Spotify so you don’t miss the next episode. And if you like what you hear, a five-star rating goes

October 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.